|
|
|
|
| LEADER |
01421nam a2200337 u 4500 |
| 001 |
EB002000698 |
| 003 |
EBX01000000000000001163599 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
210907 r ||| eng |
| 245 |
0 |
0 |
|a CADTH Canadian Drug Expert Committee recommendation: Crisaborole (Eucrisa -- Pfizer Canada Inc.)
|h Elektronische Ressource
|b indication : for topical treatment of mild-to-moderate atopic dermatitis in patients two years of age and older
|
| 246 |
3 |
1 |
|a Drug reimbursement recommendation Crisaborole (Eucrisa)
|
| 246 |
3 |
1 |
|a Crisaborole (Eucrisa -- Pfizer Canada Inc.)
|
| 250 |
|
|
|a Version 1.0
|
| 260 |
|
|
|a Ottawa (ON)
|b CADTH
|c April 2019, 2019
|
| 300 |
|
|
|a 1 PDF file (7 pages)
|
| 653 |
|
|
|a Insurance, Health, Reimbursement
|
| 653 |
|
|
|a Canada
|
| 653 |
|
|
|a Phosphodiesterase 4 Inhibitors / therapeutic use
|
| 653 |
|
|
|a Cost-Benefit Analysis
|
| 653 |
|
|
|a Boron Compounds / economics
|
| 653 |
|
|
|a Dermatitis, Atopic / drug therapy
|
| 653 |
|
|
|a Boron Compounds / therapeutic use
|
| 653 |
|
|
|a Phosphodiesterase 4 Inhibitors / economics
|
| 710 |
2 |
|
|a CADTH Canadian Drug Expert Committee
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a CADTH common drug review
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK542403
|3 Volltext
|n NLM Bookshelf Books
|3 Volltext
|
| 082 |
0 |
|
|a 610
|
| 082 |
0 |
|
|a 330
|